AKBA

Akebia Therapeutics Stock Price

2.51
0.04 (1.62%)
Upgrade to Real-Time
Regular Market
2.51

Low
2.09

52 Week Range

High
12.48

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Akebia Therapeutics Inc AKBA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 1.62% 2.51 13:41:10
Open Price Low Price High Price Close Price Prev Close
2.48 2.43 2.56 2.47
Bid Price Ask Price Spread News
2.50 2.51 0.01 - 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,864 3,372,796 $ 2.48 $ 8,371,975 - 2.09 - 12.48
Last Trade Time Type Quantity Stock Price Currency
13:42:47 48 $ 2.51 USD

Period:

Draw Mode:

Akebia Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 401.89M 160.12M 136.06M $ 295.31M $ - -2.76 -0.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 189.03k 2.00%

more financials information »

Akebia Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AKBA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.033.042.432.668,823,279-0.52-17.16%
1 Month4.254.332.433.064,567,973-1.74-40.94%
3 Months3.234.332.433.343,989,215-0.72-22.29%
6 Months3.815.142.433.584,866,061-1.30-34.12%
1 Year11.8212.482.093.355,530,001-9.31-78.76%
3 Years10.6613.782.094.562,594,216-8.15-76.45%
5 Years8.5520.252.095.321,725,200-6.04-70.64%

Akebia Therapeutics Description

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.


Your Recent History
NASDAQ
AKBA
Akebia The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.